Genmab — Marts 2020
-
God morgen. :-). J.P. Morgan. : Hård nedtur og stærkere optur. https://ugebrev.dk/flashnews/jpmorgan-haard-nedtur-og-staerkere-optur/
-
Isatuximab nu også godkendt i Europa https://borsen.dk/nyheder/generelt/sanofi-faar-positiv-anbefaling-til-darzalex-konkurrent-i-europa
-
Nedtur giver købsmuligheder i C25 https://borsen.dk/nyheder/investor/syv-aktietips-fra-aktieanalysechef-nedtur-giver-kobsmuligheder-i-c25
-
God morgen.
-
Citi løfter kursmål for Genmab: “Det seneste kursfald skaber en attraktiv gevinst for at tage risiko”
-
Citi løfter kursmål for Genmab: “Det seneste kursfald skaber en attraktiv gevinst for at tage risiko”
Selv om biotekselskabet Genmab ikke undgår at blive påvirket af coronakrisen, så mener storbanken Citi, at det danske biotekselskab faktisk er blevet mere værd i den seneste tid, og derfor er kursfald
borsen.dk (borsen.dk)
-
løfter kursmålet for Genmab til 1600 fra 1500, men ser potentiale helt op til kurs 2358
-
Pu ha.
-
Så satser Lundbeck nok endnu mere på Lu AF82422 (Genmab antibody mod Parkinson)
-
-
God morgen
-
mRNA - 1273 vaccine in clinical trial.. First in human for Covid-19. https://www.clinicaltrialsarena.com/comment/first-in-human-trial-covid-19-vaccine/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind